Interventional, open-label, flexible-dose, long-term extension study to evaluate safety of eptinezumab as preventive treatment in patients with migraine in Japan
日本人患者を対象とした片頭痛の予防療法におけるeptinezumabの長期継続投与試験
Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan
(2)治験責任医師等に関する事項
矢澤 政成
Yazawa Masanari
/
ルンドベック・ジャパン株式会社
Lundbeck Japan K.K.
105-0001
/
東京都港区虎ノ門四丁目1番17号神谷町プライムプレイス
Kamiyacho Prime Place, 4-1-17 Toranomon, Minato-ku, Tokyo
- The participant has completed the Primary Outcome Visit (Visit 5) of the lead-in Study 19140A immediately prior to enrolment into this study.
- The participant is indicated for 60-week preventive treatment of chronic migraine with eptinezumab according to the clinical opinion of the investigator.
- The participant has a serious adverse event (SAE) or a moderate or severe ongoing AE from the Lead-In study considered a potential safety risk by the investigator.
- The participant has a clinically relevant change in vital signs or electrocardiogram (ECG) from the Lead-In study considered a potential safety risk by the investigator.
- The participant has a disease or takes medication that could, in the investigator's opinion, interfere with the assessments of safety, tolerability, or efficacy, or interfere with the conduct or interpretation of the study. Other inclusion and exclusion criteria may apply.
年齢下限 / Age Minimum
18歳 以上
18age old over
年齢上限 / Age Maximum
75歳 以下
75age old under
性別 / Gender
男性・女性
Both
中止基準
対象疾患名 / Health Condition(s) or Problem(s) Studied
片頭痛
Migraine
対象疾患コード / Code
対象疾患キーワード / Keyword
介入の有無
あり
介入の内容 / Intervention(s)
Eptinezumab 100 mgまたはeptinezumab 300 mgを点滴静注する
Eptinezumab 100 mg or eptinezumab 300 mg administered intravenously
介入コード / Code
介入キーワード /Keyword
主たる評価項目 / Primary Outcome(s)
ベースラインから68週までに有害事象を発現した被験者数
Number of Participants With Adverse Events (AEs) from Baseline to Week 68